BRAF and MEK inhibition yields a high response rate in patients with metastatic BRAF-mutant melanoma, but the response is consistently temporary with inevitable development of tumour resistance. We report on a case where this treatment is used as neoadjuvant therapy in a bulky, inoperable stage 3C melanoma to locally reduce tumour load and allow delayed surgical excision. A 58 year-old female presents with rapidly growing progressing metastatic melanoma of the axilla and supraclavicular regions with an unknown primary. Due to the bulky disease and its close involvement of the neurovascular structures, initial surgical excision was deemed unsuitable without compromising limb function. The patient was treated with an 8-month course of BRAF and MEK inhibitors which resulted in a significant reduction of disease, at which point the patient underwent axillary and neck dissection with histology showing widely excised disease with large areas of tumour necrosis and small foci of viable malignant cells. We also review the small, but encouraging body of literature where BRAF is used as neoadjuvant therapy to allow surgical excision of bulky metastatic disease.